2024年10月16日,百裕制药与诺华就一款小分子抗肿瘤药物签订独家许可协议。笔者推测是DNA-PK。
-根据协议,百裕将收到7000万美元首付款,以及可达11亿美元的开发、注册及商业化等各类里程碑付款和相应特许使用费。-诺华将获得该款小分子创新药的全球独家开发及商业化权利。-这次战略合作是百裕向全球患者提供潜在抗肿瘤药物重要一步,期待积极成果实现。百裕制药总部位于中国成都,专注于药物发明发现,多次荣获国家奖项,专注银杏核心药效成分研究二十余年,成功开发现代植物药(银杏叶有效部位制剂)“银杏内酯注射液”及“银杏总内酯滴丸”。
Chengdu
Baiyu enters into a license agreement for the development and
commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, Oct.16th,
2024 -- Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today
announced that it has entered into an exclusive license agreement with
Novartis for a small molecule anti-tumor asset.
Under
the terms of the license agreement, Baiyu will receive an upfront
payment of $70 million and is eligible to receive additional
development, regulatory and commercial milestones payments of up to $1.1
billion, as well as tiered royalties.
Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset.
This
collaboration is an important step for Baiyu in making potential
anti-tumor drugs available to patients globally, and Baiyu look forward
to positive results being realized.
About Chengdu Baiyu Biopharmaceutical Co., Ltd.
Founded
in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu,
China. The company is dedicated to discover and develop innovative
medicines, for which it has earned numerous prestigious national awards.
With over 20 years of focused research on the core pharmacological
components of Ginkgo biloba, we have successfully developed modern
botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping
Pills.
声明:发表/转载本文仅仅是出于传播信息的需要,并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断,后果自负。若有侵权,告知必删!
长按关注本公众号
粉丝群/投稿/授权/广告等
请联系公众号助手
觉得本文好看,请点这里↓